EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 567 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Alcohol Tied to 750,000 Cancer Cases Worldwide in 2020 August 12, 2021 EMA Recommends Granting Marketing Authorisation for Generic Abiraterone Acetate May 4, 2021 ESMO Asia Congress 2024, Singapore, 6-8 December November 27, 2024 Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... March 27, 2021 Load more HOT NEWS FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk... Surgical Technique Helps Keep Breast Cancer Patients from Going Under the... FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait
